Cannabics pharmaceuticals engages its R&D through its subsidiary Grin Ultra – an Israeli company that has a license from the Israeli ministry of health since 2014 to perform research on cannabinoids. The company develops cannabinoid medicine for cancer patients under strict regulations of consistency and quality and examines efficacy through in-vitro studies and clinical trials.
Cannabics Capsules as Treatment to Improve Cancer Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients
The main purpose in the treatment of patients with advanced cancer and CACS is to prolong life and to improve quality of life (QoL) as far as possible. QoL in patients with CACS is directly related to loss of appetite and loss of weight. Cannabis pills are given in Israel to advanced cancer patients with various symptoms in order to improve their QoL. The purpose of this study is to examine the influence of Cannabics capsules on improving loss of appetite and loss of weight.
Based on our in vitro research data cross linked with clinical outcomes we will create a state of the art cancer related diagnostic tool which will turn cannabinoids a therapy of choice in contemporary oncology.